

NEURO-LIFT

NEURO-LIFT is a unique blend of the highest quality USP L-Tyrosine (500 mg), N-Acetyl-L-Tyrosine (100 mg), and the active, co-enzymatic form of vitamin B6 (20 mg). L-Tyrosine is a key factor in catecholamine synthesis, and clinical studies have shown that altered catecholamine levels correlate with depression in humans. NEURO-LIFT was designed to safely and effectively increase catecholamine levels.

NEURO-LIFT HIGHLIGHTS

- **Critical precursor to norepinephrine; can elevate mood level**
- **Formulated to effectively improve catecholamine levels**
- **Includes Pyridoxal-5'-Phosphate (B6) for enhanced catecholamine synthesis**
- **N-Acetyl complex for added efficiency in crossing the blood-brain barrier**

CRAIG
NUTRACEUTICALS, INC.

Airport Professional Center
3075 Alhambra Drive, Ste 206
Cameron Park CA 95682

(800) 293-1683
(530) 676-8838
(530) 676-9040 FAX
www.craignutraceuticals.com

WHAT IS L-TYROSINE?

L-Tyrosine is an amino acid that is synthesized in the body from L-Phenylalanine. Tyrosine is involved in energy production and the formation of melanin, and it plays a key role in the synthesis of thyroxin (a hormone secreted by the thyroid gland). Additionally, Tyrosine is the critical precursor to the production of the neurotransmitter dopamine and the hormones norepinephrine and epinephrine.

WHAT ARE CATECHOLAMINES?

Dopamine, norepinephrine and epinephrine are collectively known as catecholamines. In its role as a precursor in the formation of catecholamines, L-Tyrosine is first converted to dopa, and then to dopamine. Dopamine is then available for conversion to norepinephrine and epinephrine. Catecholamine deficiencies in humans have been linked to depression, and research has shown that low levels of the precursor Tyrosine are also correlated with depression. Further research has revealed that supplementation with L-Tyrosine can be clinically effective in the treatment of depression associated with catecholamine deficiencies.

WHY IS N-ACETYL-L-TYROSINE INCLUDED?

N-Acetyl-L-Tyrosine is a special Tyrosine chemical complex. Research indicates that it crosses the blood-brain barrier rapidly, and including the N-Acetyl-L-Tyrosine complex improves the effectiveness of the NEURO-LIFT formula.

L-TYROSINE AND DEPRESSION

- Low levels of norepinephrine are associated with depression, and have correlated with low levels of Tyrosine in plasma.
- Supplementation has been proven effective in raising plasma levels of Tyrosine.
- Studies support the effectiveness of Tyrosine supplementation in the treatment of catecholamine-related depression.

L-TYROSINE AND STRESS

- Reduced catecholamine levels have been associated with behavioral changes related to stress.
- Tyrosine supplementation has resulted in decreased anxiety and improvement in mood.
- Tyrosine supplementation has also resulted in increased ability to concentrate.
- Other symptoms of stress, such as headache and muscle discomfort, have been reduced after supplementation with Tyrosine.

L-TYROSINE AND COCAINE ADDICTION

- The chronic use of cocaine reduces dopamine and norepinephrine metabolites. This interferes with catecholamine biochemistry in the brain and contributes to a chemical imbalance.
- The resulting chemical imbalance influences the symptoms of cocaine withdrawal. Symptoms include depression, anxiety, irritability, reduced ability to concentrate, and drug craving, among others.
- Tyrosine levels are measurably low on those addicted to cocaine and supplementation with Tyrosine improves catecholamine biochemistry and assists in alleviating withdrawal symptoms.

L-TYROSINE AND NARCOLEPSY

- Persons with narcolepsy experience sudden, uncontrollable urges to sleep.
- This disorder is associated with a dopamine abnormality.
- The precursor to dopamine is L-Tyrosine, and studies support the benefits of Tyrosine supplementation for persons with narcolepsy.

HIGHLIGHTS AND BENEFITS OF NEURO-LIFT

- CNI uses only the highest quality L-Tyrosine, N-Acetyl-L-Tyrosine, and Pyridoxal-5'-Phosphate.
- N-Acetyl-L-Tyrosine readily crosses the blood barrier. It is included in this formula for fast assimilation and increased effectiveness.
- Pyridoxal-5'-Phosphate (active, co-enzymatic B6) is necessary for proper catecholamine synthesis. It is included in the formulation of NEURO-LIFT for this reason.
- NEURO-LIFT is encapsulated for quick digestion and assimilation. Desiccant pads ensure freshness.

SAFETY CONSIDERATION

L-Tyrosine is a natural amino acid that has been used safely for over 20 years with no adverse side effects. However, L-Tyrosine and formulations containing L-Tyrosine should not be used by individuals taking MAO inhibitors. In addition, persons with melanomas should not supplement with L-Tyrosine because it is involved in the production of melanin.

REFERENCES

- Alonso, R., Gibson, C., Wurtman, R.J., Agharanya, J.C., & Prieto, L. (1982). Elevation of urinary catecholamines and their metabolites following tyrosine administration in humans. *Biol. Psych.* 17(7), 781-790.
- Dackle, C.A. & Gold, M.S. (1985). *Journal of Substance Abuse Treatment*.
- Dakshinamurti, K. (1982). Neurobiology of pyridoxine. In H. Draper (Ed.), *Advances in Nutritional Research*. (Vol 4, pp.143-179). New York: Plenum Press.
- Gibson, C. (1983). Control of monoamine synthesis by amino acid precursors. *Adv. Biol. Psychiat.* 10, 4-18.
- Gibson C., & Gelenberg, A. (1983). Tyrosine for the treatment of depression. *Adv Biol Psychiat.* 10, 148-59.
- Hitri, A., Casanova, M., Kleinman, J., & Wyatt, R. (1994). Fewer dopamine transporter receptors in the prefrontal cortex of cocaine users. *Am.J.Psychiatry*, 151, 1074-1076.
- Kishimoto, H., Hama, Y., Nagasaki, T., & Konno, M. (1978). Plasma amino acid concentrations in depressed patients. *Yokoham Med. Bul.*
- Moller, S.E., Odum, K., Kirk, L., Bjerre, M., Fog-Moller, F., & Knudsen, A. (1985). Plasma tyrosine/neutral amino acid ratio correlated with clinical response to nortriptyline in endogenously depressed patients. *J Affect Disord.* Nov; 9(3), 223-9.
- Montgomery, S., & Corn, T.H. (1994). *Psychopharmacology of depression*. Oxford University Press, Oxford, UK.
- Roufs, J.B. (1990). L-tyrosine in the treatment of narcolepsy. *Med Hypotheses.* 33(4), 269-73.
- Salter, C. (1989). Dietary tyrosine as an aid to stress resistance among troops. *Mil Med.* Mar; 154(3), 144-6.
- Stone, E.A. (1975). Stress and catecholamines. In A.J. Friedhoff (Ed.), *Catecholamines and Behavior 2: Neuropsychopharmacology* (pp. 31-72). New York: Plenum Press.
- Wurtman, R., Hefti, F., & Melamed, E. (1981). Precursor control of neurotransmitter synthesis. *Pharmac. Rev.* 32, 315-335.